PUBLIC EQUITY RESEARCH
Micron Technology, Inc. - Common Stock
United States · MU
- Latest published edition
- 2026.07.18.1
- Report generated
- July 18, 2026
Reviewed research summary
Published research overview
The public summary is arranged into shorter paragraphs for faster scanning without changing its published wording.
This in-depth due diligence report on Micron Technology, with a research cutoff date of July 18, 2026, delivers a Hold investment recommendation advising investors to wait for a better entry price, based on a $853.20 per share reference price, 12-month probability-weighted target price of $816, and an expected 12-month return of -4.4%.
Micron’s business quality has improved structurally: HBM4 has entered high-volume production for NVIDIA’s Vera Rubin platform, HBM4E is on track for 2027 mass production, and 16 strategic customer agreements (SCAs) represent roughly $100 billion in minimum contracted revenue plus $22 billion in customer cash commitments, establishing a partial earnings floor and reducing revenue volatility.
The company’s financial performance in FY2026 Q3 was record-setting, with $41.456 billion in revenue, 84.6% GAAP gross margin, $24.67 in GAAP EPS, and $18.3 billion in adjusted free cash flow, supported by tight DRAM and NAND supply conditions that management expects to persist beyond 2027. The report frames Micron’s core business as a combination of cyclical DRAM and NAND exposure plus structural HBM growth, with earnings currently driven primarily by pricing and product mix gains rather than wafer output growth, meaning earnings elasticity will decline rapidly as price increase momentum slows.
The memory cycle is assessed as being in a late-cycle overheating phase, with a composite score of 79/100: prices are still rising but at a decelerating rate, customer affordability for consumer memory products is weakening, and market discourse has shifted to extrapolating prolonged supply tightness, a pattern that typically precedes cyclical peaks. Competitively, Micron holds an upper-tier position in the second tier of the HBM market, with an estimated 21% global HBM revenue share in 2025, lagging leader SK hynix at 61% but outpacing Samsung, which is rapidly regaining HBM competitiveness and deepening its AMD partnership.
The report models mid-cycle EPS of $55-$70 per share, and its valuation framework—combining peak-earnings P/E, mid-cycle P/E, and discounted cash flow analysis—produces a fair-value range of $760-$900 per share, with a base fair value of approximately $840, indicating the current price offers only a minimal margin of safety. Material risks include cooling AI capital expenditure expectations, Samsung and SK hynix extending their HBM leadership, conventional DRAM and NAND prices declining ahead of HBM in 2027, and Chinese suppliers CXMT and YMTC expanding capacity in mature memory products to compress pricing for Micron’s non-HBM segments.
Positive catalysts include an FY2026 Q4 earnings beat, meaningful growth in SCA customer cash deposits in early 2027, and better-than-expected HBM4E development timelines and yields. The report recommends staged accumulation only if shares pull back below $780, with maximum position sizes of 4% for conservative investors, 7% for balanced investors, and 10% for aggressive investors, noting that the Kelly Fraction at the current price is negative, signaling no positive expected-value edge for new positions.
Report directory
Core modules included in this edition
- 01Research Scope and Key Snapshot
- 02Executive Summary and Core Conclusions
- 03Bull and Bear Thesis Comparison
- 04Key Disputes, Catalysts, and Conclusion
- 05Industry Cycle and Business-Quality Re-Rating
- 06Revenue, Gross-Profit, and Free-Cash-Flow Trees
- 07Memory-Cycle Thermometer
- 08HBM Deep-Dive Assessment
- 09HBM Revenue Bottom-Up Model
- 10Competitive Landscape and China Stress Test
- 11Financial Forecasts and Valuation
- 12Trade Execution and Risk Control
- 13Catalysts and Quarterly Monitoring Dashboard
- 14Kill Thesis Checklist
- 15Red-Team Rebuttal and Final Investment Committee Conclusion